

Paris, august 24<sup>th</sup>, 2015

## Disclosure of the total number of voting rights and the number of shares of the share capital

**Quantum Genomics (Alternext - FR0011648971 - ALQGC)**, a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, has published information on the total number of voting rights and number of shares comprising the share capital on august 23<sup>rd</sup> 2015, in accordance with the provisions of article 223-16.

Date	Number of shares	Number of voting rights	
		Theoretical	
August 23 <sup>rd</sup> 2015	6,927,334		8,187,326
		Exercisable <sup>(1)</sup>	8,163,991

(1) The total number of voting rights is calculated based on the total shares minus shares without voting rights treasury shares. On august 23<sup>rd</sup> 2015, 23,335 shares, representing a total of 23,335 voting rights, were registered under the liquidity contract assigned to the brokerage Invest Securities.

### CONTACTS

**Quantum Genomics**

Lionel Ségard  
Chairman & Chief Executive Officer  
01 60 13 76 80

**Quantum Genomics**

Marc Karako  
CFO – Investor Relations  
01 60 13 76 84  
[marc.karako@quantum-genomics.com](mailto:marc.karako@quantum-genomics.com)

**ACTUS finance et communication**

Jean-Michel Marmillon  
Press Relations  
01 53 67 36 73  
[jmmarmillon@actus.fr](mailto:jmmarmillon@actus.fr)

### ABOUT QUANTUM GENOMICS

Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially high blood pressure and heart failure.

Quantum Genomics is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than 20 years of academic research in the laboratories of the Collège de France, INSERM, CNRS and the University of Paris Descartes.

Quantum Genomics is listed on the Alternext market in Paris (ISIN code FR0011648971, Ticker ALQGC).